CTI Pharma and Medical Services provides you with various genotoxic impurity analysis method development and validation services. The analytical method development meets the requirements of the ICH Q14 the analytical method validation meets the requirements of the ICHQ2(R2), USP General Chapter <1225>, ChP General Chapter <9101> and other regulations.